# Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS

> **NCT02912325** · NA · COMPLETED · sponsor: **MDM S.p.A.** · enrollment: 34 (actual)

## Conditions studied

- Metabolic Syndrome

## Interventions

- **DIETARY_SUPPLEMENT:** Daily administration: 2 tablets FaseMETS a day

## Key facts

- **NCT ID:** NCT02912325
- **Lead sponsor:** MDM S.p.A.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-09
- **Primary completion:** 2017-10-15
- **Final completion:** 2018-06-11
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02912325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02912325, "Non-Comparative Study to Assess the Efficacy and Safety of the New Food Supplement FaseMETS". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT02912325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*